|
1
|
Tharmapalan P, Mahendralingam M, Berman HK
and Khokha R: Mammary stem cells and progenitors: Targeting the
roots of breast cancer for prevention. EMBO J.
15(e100852)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Garrido-Castro AC, Lin NU and Polyak K:
Insights into molecular classifications of triple-negative breast
cancer: Improving patient selection for treatment. Cancer Discov.
9:176–198. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nedeljković M and Damjanović A: Mechanisms
of chemotherapy resistance in triple-negative breast cancer-how we
can rise to the challenge. Cells. 8(957)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Synnott NC, Murray A, McGowan PM, Kiely M,
Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J and Duffy
MJ: Mutant p53: A novel target for the treatment of patients with
triple-negative breast cancer? Int J Cancer. 140:234–246.
2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cordani M, Pacchiana R, Butera G, D'Orazi
G, Scarpa A and Donadelli M: Mutant p53 proteins alter cancer cell
secretome and tumour microenvironment: Involvement in cancer
invasion and metastasis. Cancer Lett. 376:303–309. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tan BS, Tiong KH, Choo HL, Chung FFL, Hii
LW, Tan SH, Yap IK, Pani S, Khor NT, Wong SF, et al: Mutant
p53-R273H mediates cancer cell survival and anoikis resistance
through AKT-dependent suppression of BCL2-modifying factor (BMF).
Cell Death Dis. 6(e1826)2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bertoli G, Cava C, Diceglie C, Martelli C,
Rizzo G, Piccotti F, Ottobrini L and Castiglioni I: MicroRNA-567
dysregulation contributes to carcinogenesis of breast cancer,
targeting tumor cell proliferation, and migration. Breast Cancer
Res Treat. 161:605–616. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ren Y, Chen Y, Liang X, Lu Y, Pan W and
Yang M: miRNA-638 promotes autophagy and malignant phenotypes of
cancer cells via directly suppressing DACT3. Cancer Lett.
390:126–136. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Li Z, Meng Q, Pan A, Wu X, Cui J, Wang Y
and Li L: MicroRNA-455-3p promotes invasion and migration in triple
negative breast cancer by targeting tumor suppressor EI24.
Oncotarget. 8:19455–19466. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Humphries B and Yang C: The microRNA-200
family: Small molecules with novel roles in cancer development,
progression and therapy. Oncotarget. 6:6472–6498. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chikh A, Ferro R, Abbott JJ, Piñeiro R,
Buus R, Iezzi M, Ricci F, Bergamaschi D, Ostano P, Chiorino G, et
al: Class II phosphoinositide 3-kinase C2β regulates a novel
signaling pathway involved in breast cancer progression.
Oncotarget. 7:18325–18345. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Noonan EJ, Place RF, Pookot D, Basak S,
Whitson JM, Hirata H, Giardina C and Dahiya R: miR-449a targets
HDAC-1 and induces growth arrest in prostate cancer. Oncogene.
28:1714–1724. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jeon HS, Lee SY, Lee EJ, Yun SC, Cha EJ,
Choi E, Na MJ, Park JY, Kang J and Son JW: Combining
microRNA-449a/b with a HDAC inhibitor has a synergistic effect on
growth arrest in lung cancer. Lung Cancer. 76:171–176.
2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Stojanovic N, Hassan Z, Wirth M, Wenzel P,
Beyer M, Schäfer C, Brand P, Kroemer A, Stauber RH, Schmid RM, et
al: HDAC1 and HDAC2 integrate the expression of p53 mutants in
pancreatic cancer. Oncogene. 36:1804–1815. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sun X, Liu S, Chen P, Fu D, Hou Y, Hu J,
Liu Z, Jiang Y, Cao X, Cheng C, et al: miR-449a inhibits colorectal
cancer progression by targeting SATB2. Oncotarget. 8:100975–100988.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chen SP, Liu BX, Xu J, Pei XF, Liao YJ,
Yuan F and Zheng F: miR-449a suppresses the epithelial-mesenchymal
transition and metastasis of hepatocellular carcinoma by multiple
targets. BMC Cancer. 15(706)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Luo W, Huang B, Li Z, Li H, Sun L, Zhang
Q, Qiu X and Wang E: MicroRNA-449a is downregulated in non-small
cell lung cancer and inhibits migration and invasion by targeting
c-Met. PLoS One. 8(e64759)2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wei B, Song Y, Zhang Y and Hu M:
MicroRNA-449a functions as a tumor-suppressor in gastric
adenocarcinoma by targeting Bcl-2. Oncol Lett. 6:1713–1718.
2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Subramanian M, Francis P, Bilke S, Li XL,
Hara T, Lu X, Jones MF, Walker RL, Zhu Y, Pineda M, et al: A mutant
p53/let-7i-axis-regulated gene network drives cell migration,
invasion and metastasis. Oncogene. 34:1094–1104. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang S, Zhou L, Hong B, van den Heuvel
AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L and
El-Deiry WS: Small-molecule NSC59984 restores p53 pathway signaling
and antitumor effects against colorectal cancer via p73 activation
and degradation of mutant p53. Cancer Res. 75:3842–3852.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jung CL, Mun H, Jo SY, Oh JH, Lee C, Choi
EK, Jang SJ and Suh YA: Suppression of gain-of-function mutant p53
with metabolic inhibitors reduces tumor growth in vivo. Oncotarget.
7:77664–77682. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen T, You Y, Jiang H and Wang ZZ:
Epithelial-mesenchymal transition (EMT): A biological process in
the development, stem cell differentiation, and tumorigenesis. J
Cell Physiol. 232:3261–3272. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tao Y, Han T, Zhang T, Ma C and Sun C:
LncRNA CHRF-induced miR-489 loss promotes metastasis of colorectal
cancer via TWIST1/EMT signaling pathway. Oncotarget. 8:36410–36422.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Heerboth S, Housman G, Leary M, Longacre
M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor
metastasis. Clin Transl Med. 4(6)2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hori S, Wadhwa K, Pisupati V, Zecchini V,
Ramos-Montoya A, Warren AY, Neal DE and Gnanapragasam VJ: Loss of
hSef promotes metastasis through upregulation of EMT in prostate
cancer. Int J Cancer. 140:1881–1887. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kim T, Veronese A, Pichiorri F, Lee TJ,
Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, et al:
p53 regulates epithelial-mesenchymal transition through microRNAs
targeting ZEB1 and ZEB2. J Exp Med. 208:875–883. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Dong P, Karaayvaz M, Jia N, Kaneuchi M,
Hamada J, Watari H, Sudo S, Ju J and Sakuragi N: Mutant p53
gain-of-function induces epithelial-mesenchymal transition through
modulation of the miR-130b-ZEB1 axis. Oncogene. 32:3286–3295.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hosain SB, Khiste SK, Uddin MB, Vorubindi
V, Ingram C, Zhang S, Hill RA, Gu X and Liu YY: Inhibition of
glucosylceramide synthase eliminates the oncogenic function of p53
R273H mutant in the epithelial-mesenchymal transition and induced
pluripotency of colon cancer cells. Oncotarget. 7:60575–60592.
2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Raha P, Thomas S, Thurn KT, Park J and
Munster PN: Combined histone deacetylase inhibition and tamoxifen
induces apoptosis in tamoxifen-resistant breast cancer models, by
reversing Bcl-2 overexpression. Breast Cancer Res.
17(26)2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Shoja MH, Reddy ND, Nayak PG, Srinivasan
KK and Rao CM: Glycosmis pentaphylla (Retz.) DC arrests cell cycle
and induces apoptosis via caspase-3/7 activation in breast cancer
cells. J Ethnopharmacol. 168:50–60. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
You J, Zhang Y, Li Y, Fang N, Liu B, Zu L
and Zhou Q: miR-449a suppresses cell invasion by inhibiting MAP2K1
in non-small cell lung cancer. Am J Cancer Res. 5:2730–2744.
2015.PubMed/NCBI
|
|
38
|
Noonan EJ, Place RF, Basak S, Pookot D and
Li LC: miR-449a causes Rb-dependent cell cycle arrest and
senescence in prostate cancer cells. Oncotarget. 1:349–358.
2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kumar P, Sharad S, Petrovics G, Mohamed A,
Dobi A, Sreenath TL, Srivastava S and Biswas R: Loss of miR-449a in
ERG-associated prostate cancer promotes the invasive phenotype by
inducing SIRT1. Oncotarget. 7:22791–22806. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Shi W, Bruce J, Lee M, Yue S, Rowe M,
Pintilie M, Kogo R, Bissey PA, Fyles A, Yip KW and Liu FF: miR-449a
promotes breast cancer progression by targeting CRIP2. Oncotarget.
7:18906–18918. 2016.PubMed/NCBI View Article : Google Scholar
|
